Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2013

Open Access 01-12-2013 | Review

Oral squamous cell carcinoma in relation to field precancerisation: pathobiology

Authors: Liviu L Feller, Razia RAG Khammissa, Beverly B Kramer, Johan J Lemmer

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Abstract

Squamous cell carcinoma of the oral cavity evolves within a field of precancerized oral epithelium containing keratinocytes at different stages of transformation. Following acquisition of additional genetic alterations, these precancerous keratinocytes may become cancerous.
Persons with apparently successfully treated oral squamous cell carcinoma are at high risk of developing a new carcinoma at, or close to the site of the treated tumour. This second carcinoma may have developed either from malignant keratinocytes left behind at surgery (recurrence), or from transformed keratinocytes within the field of precancerized epithelium from which the primary carcinoma had arisen (new carcinoma).
The cells of the new carcinoma may have genetic changes in common with the cells of the original carcinoma because both are descended from a proliferating monoclone within the precancerized field; but if the new cancer originates from a different clone, it may have a dissimilar genetic profile even if the original and the new carcinoma are closely contiguous.
The purpose of this article is to review the pathobiology of oral squamous cell carcinoma in relation to fields of precancerised oral epithelium.
Appendix
Available only for authorised users
Literature
1.
Rapidis AD, Gullane P, Langdon JD, Lefebvre JL, Scully C, Shah JP: Major advances in the knowledge and understanding of the epidemiology, aetiopathogenesis, diagnosis, management and prognosis of oral cancer. Oral Oncol. 2009, 45: 299-300. 10.1016/j.oraloncology.2009.04.001.CrossRefPubMed
2.
Scully C, Bagan J: Oral squamous cell carcinoma overview. Oral Oncol. 2009, 45: 301-308. 10.1016/j.oraloncology.2009.01.004.CrossRefPubMed
3.
Bagan J, Sarrion G, Jimenez Y: Oral cancer: clinical features. Oral Oncol. 2010, 46: 414-417. 10.1016/j.oraloncology.2010.03.009.CrossRefPubMed
4.
Bello IO, Soini Y, Salo T: Prognostic evaluation of oral tongue cancer: means, markers and perspectives (I). Oral Oncol. 2010, 46: 630-635. 10.1016/j.oraloncology.2010.06.006.CrossRefPubMed
5.
6.
Braakhuis BJ, Bloemena E, Leemans CR, Brakenhoff RH: Molecular analysis of surgical margins in head and neck cancer: more than a marginal issue. Oral Oncol. 2010, 46: 485-491. 10.1016/j.oraloncology.2010.01.019.CrossRefPubMed
7.
Kurita H, Nakanishi Y, Nishizawa R, Xiao T, Kamata T, Koike T, Kobayashi H: Impact of different surgical margin conditions on local recurrence of oral squamous cell carcinoma. Oral Oncol. 2010, 46: 814-817. 10.1016/j.oraloncology.2010.08.014.CrossRefPubMed
8.
Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Van Der Wal JE, Snow GB, Leemans CR, Braakhuis BJ: Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am J Pathol. 2002, 161: 1051-1060. 10.1016/S0002-9440(10)64266-6.PubMedCentralCrossRefPubMed
9.
van Houten VM, Leemans CR, Kummer JA, Dijkstra J, Kuik DJ, van den Brekel MW, Snow GB, Brakenhoff RH: Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res. 2004, 10: 3614-3620. 10.1158/1078-0432.CCR-03-0631.CrossRefPubMed
10.
Feller L, Lemmer J: Oral Squamous Cell Carcinoma: Epidemiology, Clinical Presentation and Treatment. J Cancer Ther. 2012, 3: 263-268. 10.4236/jct.2012.34037.CrossRef
11.
Squier CA, Kremer MJ: Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr. 2001, 29: 7-15.CrossRefPubMed
12.
Miller S, Sun T, Coulombe P: Epidermal growth and differentiation. Fitzpatrick's Dermatology in General Medicine. Edited by: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Leffell D. 2008, New York: McGraw-Hill, 357-383.
13.
Nanci A: Oral mucosa. Ten Cate's Oral Histology Development structure and function. Edited by: Nanci A. 2008, Missouri: Mosby Elsevier, 318-357. 7
14.
Feller L, Lemmer J: Cancer metastasis: A short account. SADJ. 2011, 66: 180-183.PubMed
15.
Pardal R, Clarke MF, Morrison SJ: Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003, 3: 895-902. 10.1038/nrc1232.CrossRefPubMed
16.
Dalerba P, Cho RW, Clarke MF: Cancer stem cells: models and concepts. Annu Rev Med. 2007, 58: 267-284. 10.1146/annurev.med.58.062105.204854.CrossRefPubMed
17.
Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS: Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 2009, 45: 324-334. 10.1016/j.oraloncology.2008.07.011.PubMedCentralCrossRefPubMed
18.
Feller L, Bouckaert M, Chikte UM, Wood NH, Khammissa RA, Meyerov R, Lemmer J: A short account of cancer-specifically in relation to squamous cell carcinoma. SADJ. 2010, 65: 322-324.PubMed
19.
Sayed SI, Dwivedi RC, Katna R, Garg A, Pathak KA, Nutting CM, Rhys-Evans P, Harrington KJ, Kazi R: Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer. Oral Oncol. 2011, 47: 237-243. 10.1016/j.oraloncology.2011.02.009.CrossRefPubMed
20.
Fenton R, Longo D: Cancer Cell Biology and Angiogenesis. Harrison’s Principles of Internal Medicine. Edited by: Kasper D, Hauser S, Longo D, Jameson J, Loscaizo J. 2008, New York: McGraw-Hill, 498-513. 17
21.
Wicha MS, Liu S, Dontu G: Cancer stem cells: an old idea–a paradigm shift. Cancer Res. 2006, 66: 1883-1890. 10.1158/0008-5472.CAN-05-3153.CrossRefPubMed
22.
Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL: Clinical implications and utility of field cancerization. Cancer Cell Int. 2007, 7: 2-10.1186/1475-2867-7-2.PubMedCentralCrossRefPubMed
23.
Rhiner C, Moreno E: Super competition as a possible mechanism to pioneer precancerous fields. Carcinogenesis. 2009, 30: 723-728. 10.1093/carcin/bgp003.CrossRefPubMed
24.
Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ: Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer. 2005, 5: 899-904.CrossRefPubMed
25.
Jameson J, Johnson B: Paraneoplastic Syndromes: Endocrinologic/ Hematologic. Harrison’s Principles of Internal Medicine. Edited by: Kasper D, Hauser S, Longo D, Jameson J, Loscaizo J. 2008, New York: McGraw-Hill, 617-623. 17
26.
Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 2001, 414: 105-111. 10.1038/35102167.CrossRefPubMed
27.
28.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
29.
Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med. 2004, 10: 789-799. 10.1038/nm1087.CrossRefPubMed
30.
Feller L, Lemmer J: Field Cancerization and Oral Leukoplakia. Field Cancerization: Basic Science and Clinical Applications. Edited by: Dakubo GD. 2011, Ontario, Canada: Nova Science Publishers, 95-111.
31.
Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH: A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003, 63: 1727-1730.PubMed
32.
Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ: Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res. 2004, 10: 3607-3613. 10.1158/1078-0432.CCR-03-0632.CrossRefPubMed
33.
Tabor MP, Brakenhoff RH, van Houten VM, Kummer JA, Snel MH, Snijders PJ, Snow GB, Leemans CR, Braakhuis BJ: Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res. 2001, 7: 1523-1532.PubMed
34.
Braakhuis BJ, Brakenhoff RH, Leemans CR: Second field tumors: a new opportunity for cancer prevention?. Oncologist. 2005, 10: 493-500. 10.1634/theoncologist.10-7-493.CrossRefPubMed
35.
Jang SJ, Chiba I, Hirai A, Hong WK, Mao L: Multiple oral squamous epithelial lesions: are they genetically related?. Oncogene. 2001, 20: 2235-2242. 10.1038/sj.onc.1204311.CrossRefPubMed
36.
van Oijen MG, Slootweg PJ: Oral field cancerization: carcinogen-induced independent events or micrometastatic deposits?. Cancer Epidemiol Biomarkers Prev. 2000, 9: 249-256.PubMed
37.
Tomlinson I, Bodmer W: Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nat Med. 1999, 5: 11-12. 10.1038/4687.CrossRefPubMed
38.
Bodmer IW: In response to: L. A. Loeb, J. H. Bielas, and R. A. Beckman, Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 2008, 68: 3551-3557. 10.1158/0008-5472.CAN-07-5835.CrossRef
39.
Cahill DP, Kinzler KW, Vogelstein B, Lengauer C: Genetic instability and darwinian selection in tumours. Trends Cell Biol. 1999, 9: 57-60. 10.1016/S0962-8924(98)01434-2.CrossRef
40.
Rubin H: Fields and field cancerization: the preneoplastic origins of cancer: asymptomatic hyperplastic fields are precursors of neoplasia, and their progression to tumors can be tracked by saturation density in culture. Bioessays. 2011, 33: 224-231. 10.1002/bies.201000067.CrossRefPubMed
41.
Merlo LM, Pepper JW, Reid BJ, Maley CC: Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006, 6: 924-935. 10.1038/nrc2013.CrossRefPubMed
42.
Warnakulasuriya S: Histological grading of oral epithelial dysplasia: revisited. J Pathol. 2001, 194: 294-297. 10.1002/1096-9896(200107)194:3<294::AID-PATH911>3.0.CO;2-Q.CrossRefPubMed
43.
Warnakulasuriya S: Lack of molecular markers to predict malignant potential of oral precancer. J Pathol. 2000, 190: 407-409. 10.1002/(SICI)1096-9896(200003)190:4<407::AID-PATH546>3.0.CO;2-D.CrossRefPubMed
44.
Reibel J: Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med. 2003, 14: 47-62. 10.1177/154411130301400105.CrossRefPubMed
45.
Scully C, Sudbo J, Speight PM: Progress in determining the malignant potential of oral lesions. J Oral Pathol Med. 2003, 32: 251-256. 10.1034/j.1600-0714.2003.00108.x.CrossRefPubMed
46.
Kim MM, Califano JA: Molecular pathology of head-and-neck cancer. Int J Cancer. 2004, 112: 545-553. 10.1002/ijc.20379.CrossRefPubMed
47.
Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, Hittelman W, Hong WK: Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med. 1996, 2: 682-685. 10.1038/nm0696-682.CrossRefPubMed
48.
Zhang L, Williams M, Poh CF, Laronde D, Epstein JB, Durham S, Nakamura H, Berean K, Hovan A, Le ND: Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome. Cancer Res. 2005, 65: 8017-8021.PubMed
49.
Zhang L, Rosin MP: Loss of heterozygosity: a potential tool in management of oral premalignant lesions?. J Oral Pathol Med. 2001, 30: 513-520. 10.1034/j.1600-0714.2001.300901.x.CrossRefPubMed
50.
Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, Berean K, Epstein JB, Priddy R, Le ND: Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 2000, 6: 357-362.PubMed
51.
Greenspan D, Jordan RC: The white lesion that kills–aneuploid dysplastic oral leukoplakia. N Engl J Med. 2004, 350: 1382-1384. 10.1056/NEJMp048028.CrossRefPubMed
52.
Wu CJ: CLL clonal heterogeneity: an ecology of competing subpopulations. Blood. 2012, 120: 4117-4118. 10.1182/blood-2012-09-452805.CrossRefPubMed
53.
Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD, Betensky RA: Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011, 20: 810-817. 10.1016/j.ccr.2011.11.005.CrossRefPubMed
54.
Schuh A, Becq J, Humphray S, Alexa A, Burns A, Clifford R, Feller SM, Grocock R, Henderson S, Khrebtukova I: Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood. 2012, 120: 4191-4196. 10.1182/blood-2012-05-433540.CrossRefPubMed
55.
Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L: Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013, 152: 714-726. 10.1016/j.cell.2013.01.019.PubMedCentralCrossRefPubMed
56.
Tlsty TD, Briot A, Gualberto A, Hall I, Hess S, Hixon M, Kuppuswamy D, Romanov S, Sage M, White A: Genomic instability and cancer. Mutat Res. 1995, 337: 1-7. 10.1016/0921-8777(95)00016-D.CrossRefPubMed
57.
Loeb LA: A mutator phenotype in cancer. Cancer Res. 2001, 61: 3230-3239.PubMed
58.
Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature. 1998, 396: 643-649. 10.1038/25292.CrossRefPubMed
59.
Feller L, Wood NH, Motswaledi MH, Khammissa RA, Meyer M, Lemmer J: Xeroderma pigmentosum: a case report and review of the literature. J Prev Med Hygiene. 2010, 51: 87-91.
60.
Loeb LA, Bielas JH, Beckman RA: Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 2008, 68: 3551-3557. 10.1158/0008-5472.CAN-07-5835.CrossRefPubMed
61.
62.
Negrini S, Gorgoulis VG, Halazonetis TD: Genomic instability–an evolving hallmark of cancer. Nature Rev Mol Ccell Biol. 2010, 11: 220-228. 10.1038/nrm2858.CrossRef
63.
Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT: Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene. 2004, 23: 1000-1004. 10.1038/sj.onc.1207256.CrossRefPubMed
64.
van Zeeburg HJ, Snijders PJ, Wu T, Gluckman E, Soulier J, Surralles J, Castella M, van der Wal JE, Wennerberg J, Califano J: Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst. 2008, 100: 1649-1653. 10.1093/jnci/djn366.PubMedCentralCrossRefPubMed
65.
Kutler DI, Auerbach AD, Satagopan J, Giampietro PF, Batish SD, Huvos AG, Goberdhan A, Shah JP, Singh B: High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg. 2003, 129: 106-112. 10.1001/archotol.129.1.106.CrossRefPubMed
66.
Choi S, Myers JN: Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res. 2008, 87: 14-32. 10.1177/154405910808700104.CrossRefPubMed
67.
Todd R, Donoff RB, Wong DT: The molecular biology of oral carcinogenesis: toward a tumor progression model. J Oral Maxillofac Surg. 1997, 55: 613-623. 10.1016/S0278-2391(97)90495-X.CrossRefPubMed
68.
Campo-Trapero J, Cano-Sanchez J, Palacios-Sanchez B, Sanchez-Gutierrez JJ, Gonzalez-Moles MA, Bascones-Martinez A: Update on molecular pathology in oral cancer and precancer. Anticancer Res. 2008, 28: 1197-1205.PubMed
69.
Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A: The mutational landscape of head and neck squamous cell carcinoma. Science. 2011, 333: 1157-1160. 10.1126/science.1208130.PubMedCentralCrossRefPubMed
70.
Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J: Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011, 333: 1154-1157. 10.1126/science.1206923.PubMedCentralCrossRefPubMed
71.
Breivik J: The evolutionary origin of genetic instability in cancer development. Semin Cancer Biol. 2005, 15: 51-60. 10.1016/j.semcancer.2004.09.008.CrossRefPubMed
72.
Ha PK, Chang SS, Glazer CA, Califano JA, Sidransky D: Molecular techniques and genetic alterations in head and neck cancer. Oral Oncol. 2009, 45: 335-339. 10.1016/j.oraloncology.2008.05.015.PubMedCentralCrossRefPubMed
73.
Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Reboiras-Lopez MD, Gandara Rey JM, Garcia-Garcia A: Genetic and molecular alterations associated with oral squamous cell cancer (Review). Oncol Rep. 2009, 22: 1277-1282.CrossRefPubMed
74.
Duesberg P, Rausch C, Rasnick D, Hehlmann R: Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci U S A. 1998, 95: 13692-13697. 10.1073/pnas.95.23.13692.PubMedCentralCrossRefPubMed
75.
Bremmer JF, Brakenhoff RH, Broeckaert MA, Belien JA, Leemans CR, Bloemena E, van der Waal I, Braakhuis BJ: Prognostic value of DNA ploidy status in patients with oral leukoplakia. Oral Oncol. 2011, 47: 956-960. 10.1016/j.oraloncology.2011.07.025.CrossRefPubMed
76.
Torres-Rendon A, Stewart R, Craig GT, Wells M, Speight PM: DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with a high risk of malignant progression. Oral Oncol. 2009, 45: 468-473. 10.1016/j.oraloncology.2008.07.006.CrossRefPubMed
77.
van Zyl AW, van Heerden MB, Langenegger E, van Heerden WF: Correlation between dysplasia and ploidy status in oral leukoplakia. Head Neck Pathol. 2012, 6: 322-327. 10.1007/s12105-012-0352-9.PubMedCentralCrossRefPubMed
78.
Pentenero M, Giaretti W, Navone R, Demurtas A, Rostan I, Bertolusso G, Broccoletti R, Arduino PG, Malacarne D, Gandolfo S: DNA aneuploidy and dysplasia in oral potentially malignant disorders: association with cigarette smoking and site. Oral Oncol. 2009, 45: 887-890. 10.1016/j.oraloncology.2009.03.008.CrossRefPubMed
79.
Lengauer C: Aneuploidy and genetic instability in cancer. Semin Cancer Biol. 2005, 15: 1-10.1016/j.semcancer.2004.09.001.CrossRefPubMed
80.
Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak MA: Can chromosomal instability initiate tumorigenesis?. Semin Cancer Biol. 2005, 15: 43-49. 10.1016/j.semcancer.2004.09.007.CrossRefPubMed
81.
Fabarius A, Hehlmann R, Duesberg PH: Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy. Cancer Genet Cytogenet. 2003, 143: 59-72. 10.1016/S0165-4608(03)00003-7.CrossRefPubMed
Metadata
Title
Oral squamous cell carcinoma in relation to field precancerisation: pathobiology
Authors
Liviu L Feller
Razia RAG Khammissa
Beverly B Kramer
Johan J Lemmer
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-13-31

Other articles of this Issue 1/2013

Cancer Cell International 1/2013 Go to the issue

Primary research

Expression of ALDH1 in breast invasive ductal carcinoma: an independent predictor of early tumor relapse

Erratum

Erratum to: Functional disruption of macrophage migration inhibitory factor (MIF) suppresses proliferation of human h460 lung cancer cells by caspase-dependent apoptosis

Primary research

RNAi silencing of c-Myc inhibits cell migration, invasion, and proliferation in HepG2 human hepatocellular carcinoma cell line: c-Myc silencing in hepatocellular carcinoma cell

Review

Nip the HPV encoded evil in the cancer bud: HPV reshapes TRAILs and signaling landscapes

Primary research

Validation of suitable endogenous control genes for quantitative PCR analysis of microRNA gene expression in a rat model of endometrial cancer

Primary research

Low-dose etoposide-treatment induces endoreplication and cell death accompanied by cytoskeletal alterations in A549 cells: Does the response involve senescence? The possible role of vimentin
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits